Let’s(Cure)Science
Building instruments and tools to enhance private, public and community participation
ViralCure's joint strategy is the tide that raises all boats
By tackling obstacles and breaking down barriers, ViralCure brings together and motivates the essential stakeholders in the biotechnological industry.
Public Sector
National governments and international organizations concerned with the public provision of healthcare.
CROs
Contract Research Organizations that take care of the clinical trials and the official approval of new high-end medicines.
Communities
Engaged individuals who are willing to support impactful research and development.
CDMOs
Contract Development and Manufacturing Organizations that ensure biopharmaceuticals are manufactured and distributed.
Scientists
Researchers, laboratories and biotechs involved in healthcare science innovation.
Private sector
Retail and institutional investors interested in healthcare science innovation.
How to shape the future of science
Composing local units and communities into global networks of cooperation, ViralCure allows people, scientists, and institutions to connect, work and learn together.
ViralCure App
Lets individuals directly fund and engage with impactful research and development projects in a variety of ways and at different stages.
ViralCure API
Connects public healthcare providers to the products and services of the Scientists, Biotechs and Contract Organizations in the network.
ViralCure Fund
Integrates new companies, labs and organizations into the ecosystem, enabling them to access the consulting services of top-notch experts and professionals.
The ViralCure Alliance
Scientists and Institutions already participating
ViralCure collaborates with a growing network of world renowned researchers and organizations.
Daniel Douek
M.D.Ph.D
View ProfileScientific CommitteeExperience
- Senior Investigator and the Chief of the Human Immunilogy Section, Vaccine Research Center, NIAID, National Insitutes of Health, Bethesda, USA.
- Phd - Immunology at the University of London.
- Appointed to the NIH Vaccine Research Center in November 2000 and NIH Director’s Award in 2008.
- Received the World AIDS Day Award in 2007.
- One of the world’s top 50 scientists by Scientific American in 2005.
- Named as one of the 2012 POZ 100 for his significant contributions to accelerating the end of AIDS.
Dennis Burton
Ph.D
View ProfileScientific CommitteeExperience
- Scientific Director and Board Member - Mabloc.
- Chair - Immunology and Microbiology, The Scripps Research Institute, US.
- Immunologist - Massachusetts General Hospital, Harvard Medical School.
- Fellow of American Academy of Microbiology.
- Scientific Advisory Board Member - University of Lund, Sweden.
- Scientific Advisory Board Member - Krebs Institute, University of Sheffiled, UK.
- Science Committee Member - Global HIV Vaccine Initiative.
- Ph.D. - Physical Biochemistry, University of Lund, Sweden.
- First Class Honors - Oxford University.
Myrna Bonaldo
Ph.D
View ProfileScientific CommitteeExperience
- Principal investigator at the Molecular Biology of Flavivirus Laboratory, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro.
- Expert in the development of recombinant live-attenuated vaccines.
- Author of 4 patents about this vaccine development method.
- World-renowned molecular virologist.
- Collaborated in the development of antibody immunotherapy against flaviviruses and coronaviruses.
Vanderson Rocha
M.D.Ph.D
View ProfileScientific CommitteeExperience
- Doctor - Biotechnological Therapy, University of Paris 7, France.
- Professor - Hematology, Hemotherapy and Cell Therapy, Faculty of Medicine, University of São Paulo, Brazil.
- CEO - Pro-Blood Foundation.
- Consultant Professor - Oxford University, UK.
The(Cure)needs to go viral
Allies collaborating with ViralCure
